报告人：LIANGBIAO GEORGE HU（胡良彪）
报告地点：动医动科大楼401会议室
报告时间：2017年11月28日（周二）上午9:30-11:30
联系人：周向梅
电话：62732980
欢迎广大师生参加！
报告人简介：
LIANGBIAO GEORGE HU（胡良彪）研究员，美国康奈尔大学病理学硕士和病毒学博士，美国兽医病理学家和毒理学家，安进亚洲研发中心比较生物学和安全科学主任。长期以来，主要从事药物研发、疫苗研发及药物安全评价等工作。曾获NIH博士后奖学金；辉瑞2008年度成就奖，该奖项是辉瑞全球研发领域最具声望和竞争力的奖项。主持研发的Ehrlichia canis疫苗佐剂于2009年获美国专利（US 7,635,481 B2）。在Molecular Cancer Therapeutics、Antioxidants & Redox Signaling、The Journal of Pharmacology and experimental Therapeitics、Molecular Pharmaceutics等杂志发表论文多篇。
代表性论文：
1. George Hu, Mauricio Leal, Qingcong Lin, Timothy Affolter, Puja Sapra, Brian Bates, and Marc Damelin, Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody−Drug Conjugate. Molecular Pharmaceutics, December 9, 2014
2. Liangbiao George Hu and David W. Clarke, Non-clinical safety assessment of biologics, including vaccines. In: Wang & Singh editors, Biological Drug Products, Development and Strategies. Wiley & Sons, Inc: New Jersey: 2013, P. 31-56.
3. Puja Sapra, Marc Damelin, John DiJoseph, Kimberly Marquette, Kenneth G. Geles, Jonathan Golas, Maureen Dougher, Bitha Narayanan, Andreas Giannakou, Kiran Khandke, Russell Dushin, Elana Ernstoff, Judy Lucas, Mauricio Leal, George Hu, Christopher J. O’Donnell, Lioudmila Tchistiakova, Robert T. Abraham, Hans-Peter Gerber, Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells, Molecular Cancer Therapeutics, January 2013 12; 38
4. Xiaodan D. Wang, Marko Vatamaniuk, Carol A. Roneker, Matt P. Pepper, George Hu, Rebecca Simmons,and Xingen Lai. Nulls of superoxide- and hydroperoxide scavenging enzymes exert different effects on Marine islet function and pancreatic integrity. Antioxidants & Redox Signaling, accepted for publication, June 2010.
5.Stephen J. Mnich, Patrick M. Blanner, George Hu, Alexander F. Shaffer, Fernando A. Happa, Shawn O’Neil, Okechuwu Ukairo, Dave Weiss, Eric Welsh, Chad Storer, Gabriel Mbalaviele, Hidenori Ichijo, Joseph B. Monahan, Medora M.Hardy, and Hiroyuki Eda. Critical role for apoptosis signal-regulating kinase-1 in the development of inflammatory K/BxN serum-induced arthritis. Accepted for publication by International Immunopharmacology, June, 2010.
6. Cortes-Burgos, Luz A, Graneto, Matthew J, Zweifel, Ben S, Hu, George, Hardy, Medora M, Anderson, Gary D, Happa, Fernando A, Stewart, Zachary, Muthian, Shanmugam, Settle, Steven L, and Masferrer, Jaime L. CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. European Journal of Pharmacology, 2009, 617:59-67
7. Cynthia D. Sommers, Janice M. Thompson, Julia A. Guzova, Randall K. Rader, Sumathy Mathialagan, Neetu Venkatraman, Vicky Walker Holway, Larry E. Kahn, George Hu, Debra S. Garner, Horng-Chih Huang, Po-Chang Chiang, John F. Schinder, Yiding Hu, Debra M. Meyer, and Nandini N. Kishore. 2009. Novel Tight Binding Inhibitory Factor-&[kappa]B Kinase Inhibitors (IKK-2) Demonstrate Target Specific Anti-inflammatory Activities in Cellular Assays and Following Oral and Local Delivery in an In Vivo Model of Airway Inflammation. The Journal of Pharmacology and experimental Therapeitics. 330:337-388
